Company Filing History:
Years Active: 2022
Title: Mark Semenuk: Innovator in Cancer Diagnostics
Introduction
Mark Semenuk is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer diagnostics through his innovative research and development. His work focuses on identifying specific antigens and antibodies related to various types of cancer.
Latest Patents
Mark Semenuk holds a patent for "Colon and pancreas cancer specific antigens and antibodies." This invention pertains to the NPC-1 antigen on the MUC5AC protein, the 16C3 antigen on CEACAM5 and CEACAM6 proteins, and the 31.1 epitope on the A33 protein. These components are differentially expressed in cancers such as lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer. The patent outlines diagnostic and therapeutic usages of these antigens and their specific antibodies.
Career Highlights
Mark Semenuk is currently associated with Precision Biologics, Inc., where he continues to advance his research in cancer diagnostics. His work has the potential to improve diagnostic methods and therapeutic approaches for various cancers.
Collaborations
Some of his notable coworkers include Xiulian Du and Janos Luka, who contribute to the collaborative efforts in research and development at Precision Biologics, Inc.
Conclusion
Mark Semenuk's innovative work in cancer diagnostics exemplifies the impact of targeted research on improving healthcare outcomes. His contributions are paving the way for advancements in cancer treatment and diagnosis.